Bauer, Angelika
Boehme, Christian
Mayer-Suess, Lukas
Rudzki, Dagmar
Knoflach, Michael
Kiechl, Stefan
Reindl, Markus
Funding for this research was provided by:
VASCage – Centre on Clinical Stroke Research (898252)
Article History
Received: 15 December 2023
Accepted: 18 May 2024
First Online: 27 May 2024
Competing interests
: The authors declare that this study received funding from Roche Austria GmbH. The funder was involved in the study design and critical revision of the article for important intellectual content. AB was an employee of VASCage and has participated in meetings sponsored by or received travel funding from Novartis, Sanofi-Genzyme, Merck, Almirall, and Biogen. DR was an employee of VASCage. MK was an employee of VASCage and has received speaker’s honoraria, advisory honoraria and/or travel grants from Böhringer-Ingelheim, Sanofi, Daiichi-Sankyo, Novartis and Pfizer. SK is CEO of VASCage – Research Centre on Clinical Stroke Research. VASCage is a COMET Centre within the Competence Centers for Excellent Technologies (COMET) programme and funded by the Federal Ministry for Climate Action, Environment, Energy, Mobility, Innovation and Technology the Federal Ministry of Labour and Economy, and the federal states of Tyrol, Salzburg and Vienna. COMET is managed by the Austrian Research Promotion Agency (Österreichische Forschungsförderungsgesellschaft). FFG project number: 898252. MR has received a research support from Roche Austria. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.